Last updated on May 2020

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)


Brief description of study

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX) for the treatment of urinary incontinence due to overactive bladder in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.

Clinical Study Identifier: NCT02097121

Find a site near you

Start Over

Children's of Alabama

Birmingham, AL United States
  Connect »

Urologic Consultants, PC

Wyoming, MI United States
  Connect »

Carolinas Healthcare System

Charlotte, NC United States
  Connect »

St Georges Hospital

Port Elizabeth, South Africa
  Connect »